Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m² in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m².

Published in:

American Journal of Hematology, 2020, v. 95, n. 2, p. E51, doi. 10.1002/ajh.25695

By:

• Barley, Kevin;
• Sanchez, Larysa;
• Cho, Hearn J.;
• Parekh, Samir;
• Madduri, Deepu;
• Richter, Joshua;
• Isola, Luis;
• Goldstein, Talia;
• Dhadwal, Amishi;
• Zarychta, Katarzyna;
• Sanchez, Gillian Morgan;
• Catamero, Donna;
• Verina, Daniel;
• Florendo, Erika;
• Yum, Moon‐hee;
• La, Lisa;
• Gullie, Jude;
• Chan, Elaine;
• Jagannath, Sundar;
• Chari, Ajai

Publication type:

Article